Hoba Therapeutics is a Danish biotech developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide. Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease. The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.Hoba Therapeutics was founded in 2016 by Novo Holdings and Borean Innovation. Hoba Therapeutics received the Accelerator grant from the European Innovation Council in 2021 and the Grand Solution grant from Innovation Fund Denmark in 2018.About chronic neuropathic pain:Chronic neuropathic pain is a significant global health issue, affecting a substantial portion of the population worldwide. In Europe, the prevalence is estimated to be 6–8%  of the general population. Chronic neuropathic pain represents an enormous personal and economic burden.Neuropathic pain is a chronic disorder resulting from damage or dysfunction of the nervous system. Causative factors are lesions in or disorders of the nervous system, such as injury, pressure, toxic agents (e.g., chemotherapy), viral infections, and metabolic disorders. These lesions lead to aberrant functioning of sensory nerve cells, resulting in a chronic, debilitating sensation of pain.The complexity and variability of chronic neuropathic pain necessitates a multifaceted treatment approach and highlights the need for a more effective and safer treatment options. The global neuropathic pain market is estimated to be valued at USD 7.6 bn.

European Innovation Council

Novo Holdings

Borean Innovation

Hoba Therapeutics

Healthstar Communications is a full-service medical communications company.

Healthstar Communications

Affinergy is a biopharmaceutical company focused on developing treatments for serious diseases.

Affinergy

Cyclerion is a biopharmaceutical company developing novel clinical-stage assets for serious diseases.

Cyclerion

Predix Pharmaceuticals is a company focused on developing pharmaceutical treatments for neurological disorders.

Predix Pharmaceuticals

Ovid Therapeutics is a biopharmaceutical company focused on developing therapies for rare neurological disorders.

Ovid Therapeutics

Hobart Therapeutics is a biotechnology company focused on the development of innovative therapies for unmet medical needs. The company leverages cutting-edge research and development to create therapeutic solutions that aim to improve patient outcomes.

Hobart Therapeutics

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:35 AM	e910ef5e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 11, 2024 10:30 AM	10165ef8
crunchbase profile	general
li profile	general	May 14, 2024 8:35 AM	f0f1cb40
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:HOBATHERAPEUTICS

Hobart Therapeutics